ADAMTS13 and COVID-19: In another study done by Rovas et al., the MYSTIC trial, which analyzed functional and biomarker data from 23 patients admitted to hospital with COVID-19, determined that circulating VEGF-A and ADAMTS13 levels, also known as von Willebrand factor-cleaving protease, as well as sublingual glycocalyx thickness were the main markers that were associated with disease severity and predictive of whether patients will develop ARDS (Rovas et al., 2021).